

To:

8019611135

Date:

11:54 11/22/2023

From:

Pages:

8

If there are any problems with this transmission, please call:1-800-221-4008

The recipient of this patient information is prohibited from disclosing the information to any other party and is required to destroy the information after the stated need has been fulfilled. The information contained in this fax is privileged and confidential pursuant to Utah Code Ann. 26-25-7 et seq., Idaho Code Ann. 39-1392 et seq., or Wyoming Statutes 35-17-101 et seq.. If you are responsible for delivering this information to the intended recipient, you are hereby notified that any disclosure, copying, distribution, or taking of any action in reliance on the content of this information is strictly prohibited. IF YOU RECEIVE THIS TRANSMISSION IN ERROR, PLEASE NOTIFY US IMMEDIATELY to arrange for the return of the document to us.

INTERMOUNTAIN LABORATORIES - OUT PATIENT LABORATORIES

FAX LAB REPORT

MESSAGE

Reports on FAX thermal paper fade with time. If this report is to be a permanent record, a photocopy must be made.

INTERIM REPORT 11/22/2023

11:54

INTERMOUNTAIN LABORATORIES - OUT PATIENT LABORATORIES 389 South 900 East, Salt Lake City, UT 84102

MILLER, NATALIYA Z

DOB: 02201982

41Y F

Hosp #: 647504310 Bill #: 1264154478 SL Clinic Phleb 1

Home Phone #: (801)961-1138

Dr: UNAVAILABLE, PHYSICIAN, MD

H5906364 COLL: 11/16/2023 18:02 REC: 11/16/2023 18:12 PHYS: UNAVAILABLE, PHYSICIAN, MD

DHEA Sulfate, Serum

ESTRAD Comment

159

[75-410]

ug/dL

ESTRADIOL

Estradiol

<25

[<509]

pg/mL {IM}

{ IM }

{ IM }

See Comments (NOTE)

(140.113)

INTERPRETATION OF ESTRADIOL TESTING (pg/mL):

Adult

Male:

<=77

Female:

Follicular 39-189
Mid-Cycle Peak 94-508
Luteal Phase 48-309
Post-menopausal <=41

=

Source: Manufacturer's Assay Information Sheet

Result may be falsely elevated by fulvestrant (Faslodex). Estradiol in patients receiving this medication should be measured by mass spectrometry. Order code ESTMCA, Estradiol, by tandem mass spectrometry for these patients as well as for Males, Children and Postmenopausal Women.

FOLLICLE STIMULATING HORMONE

Follicle-Stimulating Hormone 2.4

2.4

mIU/mL

{OP}

FSH Comment

See Comments

(NOTE)

INTERPRETATION OF ADULT FEMALE FSH (mIU/mL):

Follicular Phase 3.0-8.1 Mid-Cycle Peak 2.6-16.7 Luteal Phase 1.4-5.5

Post-menopausal 26.7-133.4

Source: Abbott Assay Information Sheet 11/09

LUTEINIZING HORMONE (LH)

Luteinizing Hormone (LH)
LH Comment

0.:

Post-menopausal

See Comments

mU/mL

{OP}

(NOTE)

INTERPRETATION OF ADULT FEMALE LH (mIU/mL):

Follicular 1.8-11.8 Mid-Cycle Peak 7.6-89.1 Luteal 0.6-14.0

MILLER, NATALIYA Z

CONTINUED

5.2-62.0

PAGE 1

Intermountain Health

801-442-1013

Wed Nov 22 11:54:56 2023 Page 4 of 8 INTERIM REPORT

INTERMOUNTAIN LABORATORIES - OUT PATIENT LABORATORIES 389 South 900 East, Salt Lake City, UT 84102

11:54

11/22/2023

MILLER, NATALIYA Z

DOB: 02201982

41Y F

Hosp #: 647504310 Bill #: 1264154478 SL Clinic Phleb 1

Home Phone #: (801)961-1138

Dr: UNAVAILABLE, PHYSICIAN, MD

H5906364 COLL: 11/16/2023 18:02 REC: 11/16/2023 18:12 PHYS: UNAVAILABLE, PHYSICIAN, MD

LUTEINIZING HORMONE (LH)

(CONTINUED)

Source: Abbott Assay Information Sheet 12/10

Sex Hormone Binding Globulin

124

[18-178]

nmol/L

{ IM }

{OP}

MISCELLANEOUS TEST

Name of test

TESTOSTERONE FREE AND TOTAL BY ED LC MSMS FREE AND LC MSMS

TOTAL ADULT MALES

Corrected on 11/16 AT 1801: Previously reported as

TESTOSTERONE FREE AND TOTAL BY ED/LCMS

Result:

Pending Performing Lab

Source

ARUP SERUM

{OP} {OP}

{IM} = Performed at Intermountain Central Laboratory, Murray, Utah

{OP} = Performed at Salt Lake Clinic, Salt Lake City, Utah

Wed Nov 22 11:54:56 2023 Page 5 of 8 INTERIM REPORT

INTERIM REPORT 11/22/2023 11:54

INTERMOUNTAIN LABORATORIES - OUT PATIENT LABORATORIES 389 South 900 East, Salt Lake City, UT 84102

MILLER, NATALIYA Z

DOB: 02201982

41Y F

Hosp #: 647504310 Bill #: 1264163253 SL Clinic Phleb 1

Home Phone #: (801)961-1138

Dr: UNAVAILABLE, PHYSICIAN, MD

F5002655 COLL: 11/17/2023 10:	00 REC: 11/17/2023	10:18 PHYS: UNAVAILABLE	E,PHYSICIAN,MD		
Faxed to 888-539-8781 on 11/1	7/23 at 1533 NC				
Bilirubin, Direct	0.2	[0.0-0.5]	mg/dL	{OP}	
Bilirubin, Indirect	0.3	[0.2-1.3]	mg/dL	{OP}	
COMPREHENSIVE METABOLIC PANEL					
Sodium	140	[137-146]	mmol/L	{OP}	
Potassium	4.6	[3.5-5.0]	mmol/L	{OP}	
Chloride	108	[102-111]	mmol/L	{OP}	
CO2	25	[19-30]	mmol/L	{OP}	
Anion Gap (Na Cl CO2)	7	[3-16]	mmol/L	(OP)	
Glucose	92	[65-99]	mq/dL	{OP}	
BUN	11	[8-20]	mg/dL	(OP)	
Creatinine	0.68	[0.60-1.10]		{OP}	
Creatinine GFR	113	[>60]	mL/min/1.73 sq m	{OP}	
Calcium	8.9	[8.4-10.4]	mg/dL	{OP}	
Protein, Total	6.6	[6.0-8.4]	g/dL	{OP}	
Albumin	3.9	[3.5-5.2]	g/dL	{OP}	
Bilirubin, Total	0.5	[0.2-1.3]	mg/dL	{OP}	
Alkaline Phosphatase	45	[40-120]	U/L	{OP}	
ALT (SGPT)	25	[0-40]	U/L	{OP}	
AST (SGOT)	24	[9-40]	U/L	{OP}	
Comment:	See Comments			{OP}	
	(NOTE)			()	
INTERPRETATION OF ES	TIMATED GFR:				
Estimated using CKD-EPI 2021 equation					
(https://www.kidney.org/professionals/kdoqi/gfr calculator)					
Chronic Kidney Disea	se less than 60 mL/	min/1.73 sq m			
Kidney failure less than 15 mL/min/1.73 sq m					
CRP (C-Reactive Protein)	0.6	[0.0-1.5]	mg/dL	{OP}	
This test is NOT to be used for cardiovascular risk					
assessment. Order separate hsCRP assay.					
Free T4	1.04	[0.74-1.46]	ng/dL	{OP}	
PROGESTERONE					
Progesterone	0.3		ng/mL	{ IM }	
Comments:	See Comments			{ IM }	
	(NOTE)				
INTERPRETATION OF PRO	OGESTERONE:				
Reference Ranges:					
Adult					
Male:		<0.1-0.2			
Normal Men	struating Female:				
MILLER, NATALIYA Z	CONT	INUED	PAGE	1	

Wed Nov 22 11:54:56 2023 Page 6 of 8 INTERIM REPORT

11/22/2023

MI }

{IM

{ IM }

INTERMOUNTAIN LABORATORIES - OUT PATIENT LABORATORIES 389 South 900 East, Salt Lake City, UT 84102

11:54

MILLER, NATALIYA Z

DOB: 02201982

41Y F

Hosp #: 647504310 Bill #: 1264163253 SL Clinic Phleb 1

Home Phone #: (801)961-1138

Dr: UNAVAILABLE, PHYSICIAN, MD

F5002655 COLL: 11/17/2023 10:00 REC: 11/17/2023 10:18 PHYS: UNAVAILABLE, PHYSICIAN, MD

Faxed to 888-539-8781 on 11/17/23 at 1533 NC

PROGESTERONE (CONTINUED)

> Follicular <0.1-0.3 Luteal 1.2-15.9* Postmenopausal Female: <0.1-0.2

Pregnant Female:

First Trimester 2.8-147.3 Second Trimester 22.5-95.3 Third Trimester 27.9-242.5

* Luteal phase represents the central 95% interval of all values.

PROLACTIN

Prolactin 6.3 [3.6-26.5] ng/mL { IM } PROL Comment See Comments { IM }

INTERPRETATION OF PROLACTIN:

Supplementary Reference Ranges (ng/mL):

ranner Stage	Males	Females
1	<10.1	3.6-12.0
2-3	<6.1	2.6-18.0
4 - 5	2.8-11.0	3.2-20.0
Third Trime	ster	95-473

Total T3 L 75 [85-160] ng/dL

THYROID STIMULATING HORMONE

Thyroid Stimulating Hormone [0.46-4.88] uIU/mL {OP}

This is a 3rd generation TSH assay.

VITAMIN D, 25-HYDROXY

Vitamin D, 25-Hydroxy H 123 [30-80] ng/mL

Comment: See Comments

(NOTE)

INTERPRETATION OF 25-HYDROXY VITAMIN D

Reference Intervals:

Deficiency : <20 ng/mL Insufficiency : 20-29 ng/mL Optimum Level : 30-80 ng/mL Possible Toxicity : >80 ng/mL

Interpretive Data: When testing samples from patients whose predominant form of vitamin D is vitamin D2, such as patients

MILLER, NATALIYA Z CONTINUED PAGE 2

Wed Nov 22 11:54:56 2023 Page 7 of 8

11:54

INTERIM REPORT 11/22/2023

INTERMOUNTAIN LABORATORIES - OUT PATIENT LABORATORIES 389 South 900 East, Salt Lake City, UT 84102

MILLER, NATALIYA Z

DOB: 02201982

41Y F

Hosp #: 647504310

SL Clinic Phleb 1

Bill #: 1264163253 Home Phone #: (801)961-1138

Dr: UNAVAILABLE, PHYSICIAN, MD

F5002655 COLL: 11/17/2023 10:00 REC: 11/17/2023 10:18 PHYS: UNAVAILABLE, PHYSICIAN, MD

Faxed to 888-539-8781 on 11/17/23 at 1533 NC

VITAMIN D, 25-HYDROXY

(CONTINUED)

receiving vitamin D2 supplementation, results that are subtherapeutic should be confirmed with another method, such as LC-MS/MS, before being used for patient management.

Homocysteine	4	[0-11]	umol/L	{ IM}
LIPID PROFILE				
Patient Fasting?	Yes			{OP}
	15 h			
Cholesterol, Total	192	[147-199]	mg/dL	{OP}
Triglycerides	70	[45-149]	mg/dL	{OP}
HDL Cholesterol	48	[40-96]	mg/dL	{OP}
Non-HDL Cholesterol	H 144	[<130]	mg/dL	{OP
VLDL Cholesterol (Calc.)	14	[9-29]	mg/dL	{OP}
LDL Cholesterol (Calc.)	H 130	[<100]	mg/dL	{OP
Total Cholesterol:HDL Ratio LDL Comment	4.0 See Comments	[<4.5]		{OP} {OP}
	(NOTE)			
THE PROPERTY OF THE PROPERTY O				

INTERPRETIVE INFORMATION: LDL Cholesterol

The Intermountain Primary Care Clinical Program recommends that ...

for most patients without known atheroscleTosis or

risk-equivalents, use "Fooled Cohort Equation" recommendations:

http://tools.acc.org/ASCVD-Risk Estimator/

For most patients with known coronary artery disease,

atherosclerosis, diabetes mellitus, or LDL >190, target LDL <70.

---- (See "Intermountain Cardiovascular Risk and Cholesterol

. .Guideline.")

WBC RBC	5.9 4.35	[3.6-10.6] [4.20-5.40]	K/uL M/uL	{OP} {OP}
Hemoglobin	13.2	[12.0-16.0]	g/dL	{OP}
Hematocrit	39.7	[36.0-46.0]	00	{OP}
MCV	91.3	[80.0-100.0]	fL	{OP}
MCH	30.3	[26.0-34.0]	pg	{OP}
MCHC	33.2	[32.0-36.0]	q/dL	{OP}
RDW SD	43.7	[36.7-47.2]	fL	{OP}
RDW	13.0	[11.3-15.6]	90	{OP}
Platelets	267	[150-400]	K/uL	{OP}
MPV	10.9	[8.6-12.4]	fL	{OP}

11/22/2023

11:54

INTERMOUNTAIN LABORATORIES - OUT PATIENT LABORATORIES 389 South 900 East, Salt Lake City, UT 84102

MILLER, NATALIYA Z

DOB: 02201982

41Y F

Hosp #: 647504310 Bill #: 1264163253 SL Clinic Phleb 1

Home Phone #: (801)961-1138

Dr: UNAVAILABLE, PHYSICIAN, MD

F5002655 COLL: 11/17/2023 10:00 REC: 11/17/2023 10:18 PHYS: UNAVAILABLE, PHYSICIAN, MD Faxed to 888-539-8781 on 11/17/23 at 1533 NC

CBC (CONTINUED) Nucleated RBCs Automated	0.0		/100 WBCs	{OP}
DIFFERENTIAL				
Differential type	Auto			{OP}
Neutrophils	56.5		90	{OP}
Lymphocytes	32.4		90	{OP}
Monocytes	8.2		g	{OP}
Eosinophils	1.7		9	{OP}
Basophils	0.7		00	(OP)
Immature Granulocytes	0.5	[0.0-0.5]	90	{OP}
Neutrophils, Absolute	3.3	[1.8-6.8]	K/uL	{OP}
Lymphs, Absolute	1.9	[1.2-3.4]	K/uL	{OP}
Monocytes, Absolute	0.5	[0.2-0.9]	K/uL	{OP}
Eosinophils, Abs Count	0.1	[0.0-0.5]	K/uL	{OP}
Basophils, Absolute	0.0	[0.0-0.1]	K/uL	{OP}
Immature Granulocyte, Absolute		15-1 (5)		{OP}
	0.03	[0.00-0.04]	K/uL	(-1)

F5002675 COLL: 11/17/2023 10:00 REC: 11/17/2023 10:21 PHYS: UNAVAILABLE, PHYSICIAN, MD

faxed to number requested at 1153 11-17-23 dw

HEPATIC FUNCTION PANEL

6.7	[6.0-8.4]	q/dL	{OP}
3.9	[3.5-5.2]	g/dL	{OP}
0.6	[0.2-1.3]	mq/dL	{OP}
0.2	[0.0-0.5]	mg/dL	{OP}
0.4	[0.2-1.3]	mg/dL	(OP)
45	[40-120]	U/L	(OP)
23	[0-40]	U/L	{OP}
22	[9-40]	U/L	{OP}
	3.9 0.6 0.2 0.4 45	3.9 [3.5-5.2] 0.6 [0.2-1.3] 0.2 [0.0-0.5] 0.4 [0.2-1.3] 45 [40-120] 23 [0-40]	3.9 [3.5-5.2] g/dL 0.6 [0.2-1.3] mg/dL 0.2 [0.0-0.5] mg/dL 0.4 [0.2-1.3] mg/dL 45 [40-120] U/L 23 [0-40] U/L

[{]IM} = Performed at Intermountain Central Laboratory, Murray, Utah

[{]OP} = Performed at Salt Lake Clinic, Salt Lake City, Utah